Rare clinical observation of pronounced response to immunotherapy in a patient with anaplastic thyroid cancer
https://doi.org/10.17650/2222-1468-2024-14-1-63-69
Abstract
Anaplastic thyroid cancer is the rarest and the most aggressive form of thyroid cancer. It comprises 1-2 % of all cases and is characterized by rapid growth. median survival of patients with this pathology is about 5 months. Clinical manifestations of the disease are rapid deformation in the neck area, progressive respiratory distress, and dysphagia.
The article describes a clinical case of a response of unresectable, BRAF-negative, PD-L1-positive (programmed death-ligand 1) anaplastic thyroid cancer to immunotherapy with pembrolizumab.
About the Authors
D. M. Vontlaya
Multidisciplinary clinical medical center “Medical city”
Russian Federation
Russian Federation
Dinara M. Vontlaya.
32 Barnaul'skaya St., Tyumen 625000
O. V. Stryapikhina
Tyumen State Medical University, Ministry of Health of Russia
Russian Federation
Russian Federation
54 Odesskaya St., Tyumen 625023
A. A. Egorin
Multidisciplinary clinical medical center “Medical city”
Russian Federation
Russian Federation
32 Barnaul'skaya St., Tyumen 625000
A. V. Logvinenko
Multidisciplinary clinical medical center “Medical city”
Russian Federation
Russian Federation
32 Barnaul'skaya St., Tyumen 625000
R. I. Tamrazov
Multidisciplinary clinical medical center “Medical city”
Russian Federation
Russian Federation
32 Barnaul'skaya St., Tyumen 625000
References
1. Luk'yanov S.A., Sergiyko S.V., Titov S.E. et al. New opportunities for preoperative diagnosis of anaplastic thyroid cancer. Opukholi golovy i shei = Head and Neck Tumors 2021;11(1):34-40. (In Russ.). DOI: 10.17650/2222-1468-2021-11-1-34-40
2. Pylev A.L., Zhandarova A.A., Petrov K.S. et al. Anaplastic thyroid cancer. Is there a light at the end of the tunnel? Opukholi golovy i shei = Head and Neck Tumors 2020;10(1):10-9. (In Russ.). DOI: 10.17650/2222-1468-2020-10-1-10-19
3. Nikiforovich P.A., Rumyantsev P.O., Sleptsov I.V. et al. Treatment of BRAFV600E-positive anaplastic thyroid carcinoma: case report. Sibirskiy onkologicheskiy zhurnal = Siberian Journal of Oncology журнал 2020;19(5):131-44. (In Russ.). DOI: 10.21294/1814-4861-2020-19-5-131-144
4. Mudunov A.M., Pheshkhova B.G., Zeynalova P.A. et al. The difficulties of diagnosis and features of the clinical course of anaplastic thyroid cancer. A clinical case. MD-Onco 2022;2(4):22-6. (In Russ.). DOI: 10.17650/2782-3202-2022-2-4-22-26
5. Samsonov R., Burdakov V., Shtam T. et al. Plasma exosomal miR-21 and miR-181a differentiates follicular from papillary thyroid cancer. Tumour Biol 2016;37(9):12011-21. DOI: 10.1007/s13277-016-5065-3
6. Volante M., Lam A.K., Papotti M. et al. Molecular pathology of poorly differentiated and anaplastic thyroid cancer: what do pathologists need to know? Endocr Pathol 2021;32(1):63-76. DOI: 10.1007/s12022-021-09665-2
7. Santhanam P., Khthir R., Solnes L.B., Ladenson P.W. The relationship of BRAFv600e mutation status to FDG PET/CT avidity in thyroid cancer: a review and meta-analysis. Endocr Pract 2018;24(1):21-6. DOI: 10.4158/EP-2017-0080
8. FDA approves dabrafenib plus trametinib for anaplastic thyroid cancer with BRAFV600E mutation. Available at: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-dabrafenibplus-trametinib-anaplastic-thyroid-cancer-braf-v600e-mutation.
9. Naing A., Gainor J.F., Gelderblom H. et al. A first-in-human phase 1 dose escalation study of spartalizumab (PDR001), an anti-PD-1 antibody, in patients with advanced solid tumors. J Immunother Cancer 2020;8(1):e000530. DOI: 10.1136/jitc-2020-000530
10. Cabanillas M.E., Dadu R., Iyer P. et al. Acquired secondary RAS mutation in BRAFV600E-mutated thyroid cancer patients treated with BRAF inhibitors. Thyroid 2020;30(9):1288-96. DOI: 10.1089/thy.2019.0514
11. Pardoll D.M. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012;12(4):252-64.
12. Edwards S.C., Hoevenaar W.H.M., Coffelt S.B. Emerging immunotherapies for metastasis. Br J Cancer 2021;124(1):37-48. DOI: 10.1038/s41416-020-01160-5
13. Larkin J., Chiarion-Sileni V., Gonzalez R. et al. Combined nivolumab and ipilimumab or monotherapy in previously untreated melanoma. N Engl J Med 2015;373(1):23-34. DOI: 10.1056/NEJMoa1504030
14. Borel C., Jung A.C., Burgy M. Immunotherapy Breakthroughs in the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Cancer 2020;12(9):2691. DOI: 10.3390/cancers12092691
Review
For citations:
Vontlaya D.M., Stryapikhina O.V., Egorin A.A., Logvinenko A.V., Tamrazov R.I. Rare clinical observation of pronounced response to immunotherapy in a patient with anaplastic thyroid cancer. Head and Neck Tumors (HNT). 2024;14(1):63-69. (In Russ.) https://doi.org/10.17650/2222-1468-2024-14-1-63-69
Views:
356
Email this article 